Physician profile
Tamara Koss
NPI 1013989599
$23,572.28
in general payments reported to CMS, 2019-2025
42 companies · $4,727 in 2025
The $4,727 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,536 · 2020: $1,183 · 2021: $2,568 · 2022: $2,784 · 2023: $4,386 · 2024: $5,389 · 2025: $4,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,265.50 |
| Education | $236.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $2,746.01 | 2023-2025 | Zoryve |
| Abbvie INC. | $2,141.88 | 2019-2025 | |
| Leo Pharma INC. | $2,085.98 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $1,820.39 | 2019-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $1,552.94 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,442.58 | 2020-2025 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $1,200.34 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Incyte Corporation | $996.02 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $977.91 | 2022-2024 | Vtama |
| Genzyme Corporation | $896.73 | 2020-2025 | |
| Pfizer INC. | $768.46 | 2019-2025 | |
| Lilly USA, LLC | $726.82 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Almirall LLC | $689.21 | 2019-2025 | Klisyri |
| Biofrontera INC. | $677.84 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $611.86 | 2020-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Koss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.